CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
REVENUE:
Product Development and Licensing Agreements	$ 284	$ 40	$ 518	$ 117
Contracts and Grants	817	940	1,591	1,040
Product Royalties				2,334
Total Revenue	1,101	980	2,109	3,491
OPERATING EXPENSE:
Research and Development	26,185	20,417	77,355	49,597
Royalty				2,334
General and Administrative	5,004	3,578	14,373	10,128
Amortization of Acquired Intangible Assets	254	254	760	760
Total Operating Expense	31,443	24,249	92,488	62,819
Operating Loss	(30,342)	(23,269)	(90,379)	(59,328)
Investment and Other Income, Net	2,260	142	4,121	682
Interest Expense		(13)		(842)
Net Loss	(28,082)	(23,140)	(86,258)	(59,488)
Basic and Diluted Net Loss Per Common Share (Note 3) (in dollars per share)	$ (0.31)	$ (0.29)	$ (0.97)	$ (0.76)
Shares Used in Calculating Basic and Diluted Net Loss per Share (Note 3) (in shares)	89,404	81,015	89,346	78,676
COMPREHENSIVE LOSS:
Net Loss	(28,082)	(23,140)	(86,258)	(59,488)
Other Comprehensive (Loss) Income:
Foreign Currency Translation Adjustments	(3)		(4)	(3)
Unrealized Gain (Loss) on Marketable Securities	(121)	138	(40)	(56)
Comprehensive Loss	$ (28,206)	$ (23,002)	$ (86,302)	$ (59,547)